{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:08:55Z","timestamp":1788952135713,"version":"build-2803163510"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11739-020-02383-3","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T13:02:18Z","timestamp":1590498138000},"page":"801-812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?"],"prefix":"10.1007","volume":"15","author":[{"given":"Markus","family":"Depfenhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"de Villiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"Lemperle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Di Somma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"2383_CR1","unstructured":"World Health Organization (2020) Coronavirus disease (COVID-2019) press briefings. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/media-resources\/press-briefings. Accessed 22 Mar 2020"},{"key":"2383_CR2","unstructured":"World Health Organization (2020) Coronavirus Disease (COVID-2019) Situation Reports 1\u201389. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports. Accessed 18 Apr 2020"},{"issue":"20","key":"2383_CR3","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa030747","volume":"348","author":"C Drosten","year":"2003","unstructured":"Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S et al (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348(20):1967\u20131976. https:\/\/doi.org\/10.1056\/NEJMoa030747(Epub 2003\/04\/12, PubMed PMID: 12690091)","journal-title":"N Engl J Med"},{"issue":"20","key":"2383_CR4","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa030781","volume":"348","author":"TG Ksiazek","year":"2003","unstructured":"Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348(20):1953\u20131966. https:\/\/doi.org\/10.1056\/NEJMoa030781(Epub 2003\/04\/12, PubMed PMID: 12690092)","journal-title":"N Engl J Med"},{"issue":"19","key":"2383_CR5","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"AM Zaki","year":"2012","unstructured":"Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814\u20131820. https:\/\/doi.org\/10.1056\/NEJMoa1211721(Epub 2012\/10\/19, PubMed PMID: 2307514)","journal-title":"N Engl J Med"},{"key":"2383_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-0695-z","author":"AE Gorbalenya","year":"2020","unstructured":"Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA et al (2020) The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. https:\/\/doi.org\/10.1038\/s41564-020-0695-z","journal-title":"Nat Microbiol"},{"issue":"8","key":"2383_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al (2020) A Novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa2001017(Epub 2020\/01\/25, PubMed PMID: 31978945)","journal-title":"N Engl J Med"},{"key":"2383_CR8","volume-title":"Features, evaluation and treatment coronavirus (COVID-19)","author":"M Cascella","year":"2020","unstructured":"Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020) Features, evaluation and treatment coronavirus (COVID-19). StatPearls Publishing, St. Petersburg"},{"issue":"7798","key":"2383_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579(7798):265\u2013269. https:\/\/doi.org\/10.1038\/s41586-020-2008-3(Epub 2020\/02\/06, PubMed PMID: 32015508)","journal-title":"Nature"},{"issue":"1","key":"2383_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","volume":"9","author":"JF Chan","year":"2020","unstructured":"Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S et al (2020) Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 9(1):221\u2013236. https:\/\/doi.org\/10.1080\/22221751.2020.1719902(Epub 2020\/01\/29, PubMed PMID: 31987001)","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"2383_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","volume":"19","author":"G Li","year":"2020","unstructured":"Li G, De Clercq E (2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 19(3):149\u2013150. https:\/\/doi.org\/10.1038\/d41573-020-00016-0(Epub 2020\/03\/05, PubMed PMID: 32127666)","journal-title":"Nat Rev Drug Discov"},{"issue":"6483","key":"2383_CR12","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O et al (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (New York, NY) 367(6483):1260\u20131263. https:\/\/doi.org\/10.1126\/science.abb2507(Epub 2020\/02\/23, PubMed PMID: 32075877)","journal-title":"Science (New York, NY)"},{"issue":"7592","key":"2383_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature17200","volume":"531","author":"RN Kirchdoerfer","year":"2016","unstructured":"Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL et al (2016) Pre-fusion structure of a human coronavirus spike protein. Nature 531(7592):118\u2013121. https:\/\/doi.org\/10.1038\/nature17200(Epub 2016\/03\/05, PubMed PMID: 26935699; PubMed Central PMCID: PMCPMC4860016)","journal-title":"Nature"},{"issue":"10224","key":"2383_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England) 395(10224):565\u2013574. https:\/\/doi.org\/10.1016\/S0140-6736(20)30251-8(PubMed PMID: 32007145)","journal-title":"Lancet (London, England)"},{"key":"2383_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00127-20","author":"Y Wan","year":"2020","unstructured":"Wan Y, Shang J, Graham R, Baric RS, Li F (2020) Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. https:\/\/doi.org\/10.1128\/jvi.00127-20(Epub 2020\/01\/31, PubMed PMID: 31996437)","journal-title":"J Virol."},{"key":"2383_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/2020.01.26.919985","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W (2020) Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv. https:\/\/doi.org\/10.1101\/2020.01.26.919985","journal-title":"BioRxiv"},{"issue":"6891","key":"2383_CR17","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nature00786","volume":"417","author":"MA Crackower","year":"2002","unstructured":"Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE et al (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417(6891):822\u2013828. https:\/\/doi.org\/10.1038\/nature00786","journal-title":"Nature"},{"issue":"3","key":"2383_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1084\/jem.20050828","volume":"202","author":"J Gu","year":"2005","unstructured":"Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y et al (2005) Multiple organ infection and the pathogenesis of SARS. J Exp Med 202(3):415\u2013424. https:\/\/doi.org\/10.1084\/jem.20050828(Epub 2005\/07\/27)","journal-title":"J Exp Med"},{"issue":"7408","key":"2383_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature11228","volume":"487","author":"T Hashimoto","year":"2012","unstructured":"Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M et al (2012) ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487(7408):477\u2013481. https:\/\/doi.org\/10.1038\/nature11228(Epub 2012\/07\/28)","journal-title":"Nature"},{"issue":"4","key":"2383_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S2468-1253(20)30048-0","volume":"5","author":"C Yeo","year":"2020","unstructured":"Yeo C, Kaushal S, Yeo D (2020) Enteric involvement of coronaviruses: is faecal\u2013oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol 5(4):335\u2013337. https:\/\/doi.org\/10.1016\/S2468-1253(20)30048-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"23","key":"2383_CR21","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1001\/jama.2012.5669","volume":"307","author":"VM Ranieri","year":"2012","unstructured":"Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E et al (2012) Acute respiratory distress syndrome: the Berlin Definition. JAMA 307(23):2526\u20132533. https:\/\/doi.org\/10.1001\/jama.2012.5669(Epub 2012\/07\/17)","journal-title":"JAMA"},{"key":"2383_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06033-2","author":"L Gattinoni","year":"2020","unstructured":"Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L et al (2020) COVID-19 pneumonia: different respiratory treatment for different phenotypes? Intensive Care Med. https:\/\/doi.org\/10.1007\/s00134-020-06033-2","journal-title":"Intensive Care Med"},{"key":"2383_CR23","unstructured":"Craven J (2020) Covid-19 vaccine tracker. Regulatory affairs professionals society. https:\/\/www.raps.org\/news-and-articles\/news-articles\/2020\/3\/covid-19-vaccine-tracker. Accessed 30 Mar 2020"},{"issue":"3","key":"2383_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.antiviral.2013.09.028","volume":"100","author":"G Simmons","year":"2013","unstructured":"Simmons G, Zmora P, Gierer S, Heurich A, P\u00f6hlmann S (2013) Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res 100(3):605\u2013614. https:\/\/doi.org\/10.1016\/j.antiviral.2013.09.028","journal-title":"Antiviral Res"},{"issue":"6","key":"2383_CR25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3390\/v4061011","volume":"4","author":"S Belouzard","year":"2012","unstructured":"Belouzard S, Millet JK, Licitra BN, Whittaker GR (2012) Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4(6):1011\u20131033. https:\/\/doi.org\/10.3390\/v4061011(Epub 2012\/07\/21)","journal-title":"Viruses"},{"key":"2383_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052(Epub 2020\/03\/07)","journal-title":"Cell"},{"key":"2383_CR27","unstructured":"Drugs. Camostat. 2020. https:\/\/www.drugs.com\/international\/camostat.html. Accessed 22 Mar 2020"},{"issue":"1","key":"2383_CR28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s13063-019-3606-y","volume":"20","author":"ML Ramsey","year":"2019","unstructured":"Ramsey ML, Nuttall J, Hart PA, on behalf of the TIT (2019) A phase 1\/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC). Trials 20(1):501. https:\/\/doi.org\/10.1186\/s13063-019-3606-y","journal-title":"Trials"},{"key":"2383_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","volume":"116","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R, Nunneley JW et al (2015) Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 116:76\u201384. https:\/\/doi.org\/10.1016\/j.antiviral.2015.01.011","journal-title":"Antiviral Res"},{"issue":"11","key":"2383_CR30","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1128\/AAC.01043-16","volume":"60","author":"M Yamamoto","year":"2016","unstructured":"Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue J-I et al (2016) Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother 60(11):6532\u20136539. https:\/\/doi.org\/10.1128\/AAC.01043-16(PubMed PMID: 27550352)","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2383_CR31","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/2159-8290.cd-13-1010","volume":"4","author":"JM Lucas","year":"2014","unstructured":"Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD et al (2014) The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov 4(11):1310\u20131325. https:\/\/doi.org\/10.1158\/2159-8290.cd-13-1010(Epub 2014\/08\/15)","journal-title":"Cancer Discov"},{"key":"2383_CR32","doi-asserted-by":"publisher","first-page":"Cd006088","DOI":"10.1002\/14651858.CD006088.pub2","volume":"4","author":"CC Chang","year":"2007","unstructured":"Chang CC, Cheng AC, Chang AB (2007) Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst Rev 4:Cd006088. https:\/\/doi.org\/10.1002\/14651858.CD006088.pub2(Epub 2007\/10\/19)","journal-title":"Cochrane Database Syst Rev"},{"issue":"25","key":"2383_CR33","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1021\/acs.biochem.7b00429","volume":"56","author":"E Danelius","year":"2017","unstructured":"Danelius E, Andersson H, Jarvoll P, Lood K, Gr\u00e4fenstein J, Erd\u00e9lyi M (2017) Halogen bonding: a powerful tool for modulation of peptide conformation. Biochemistry 56(25):3265\u20133272. https:\/\/doi.org\/10.1021\/acs.biochem.7b00429(PubMed PMID: 28581720)","journal-title":"Biochemistry"},{"issue":"1\u20132","key":"2383_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.mce.2009.12.022","volume":"317","author":"L Mikkonen","year":"2010","unstructured":"Mikkonen L, Pihlajamaa P, Sahu B, Zhang FP, Janne OA (2010) Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol 317(1\u20132):14\u201324. https:\/\/doi.org\/10.1016\/j.mce.2009.12.022(Epub 2009\/12\/29)","journal-title":"Mol Cell Endocrinol"},{"key":"2383_CR35","unstructured":"Drugs (2020) Antiandrogens. https:\/\/www.drugs.com\/drug-class\/antiandrogens.html. Accessed 14 Apr 2020"},{"key":"2383_CR36","unstructured":"Sanofi-Synthelabo Inc. (2001) Chloroquine FDA label. https:\/\/s3-us-west-2.amazonaws.com\/drugbank\/fda_labels\/DB00608.pdf?1265922797. Accessed 22 Mar 2020"},{"issue":"3","key":"2383_CR37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ijpddr.2018.10.002","volume":"8","author":"ACC Aguiar","year":"2018","unstructured":"Aguiar ACC, Murce E, Cortopassi WA, Pimentel AS, Almeida M, Barros DCS et al (2018) Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist 8(3):459\u2013464. https:\/\/doi.org\/10.1016\/j.ijpddr.2018.10.002(Epub 2018\/11\/06)","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"1","key":"2383_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1743-422X-2-69","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG et al (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2(1):69. https:\/\/doi.org\/10.1186\/1743-422X-2-69","journal-title":"Virol J"},{"issue":"6","key":"2383_CR39","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/rheumatology\/kei282","volume":"45","author":"CH Jang","year":"2006","unstructured":"Jang CH, Choi JH, Byun MS, Jue DM (2006) Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes\/macrophages by different modes. Rheumatology (Oxford, England) 45(6):703\u2013710. https:\/\/doi.org\/10.1093\/rheumatology\/kei282(Epub 2006\/01\/19)","journal-title":"Rheumatology (Oxford, England)"},{"key":"2383_CR40","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2014.12.FOCUS14748","volume":"38","author":"E Golden","year":"2015","unstructured":"Golden E, Cho H-Y, Hofman F, Louie S, Schonthal A, Chen T (2015) Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus 38:E12. https:\/\/doi.org\/10.3171\/2014.12.FOCUS14748","journal-title":"Neurosurg Focus"},{"issue":"3","key":"2383_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269\u2013271. https:\/\/doi.org\/10.1038\/s41422-020-0282-0","journal-title":"Cell Res"},{"key":"2383_CR42","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.16.20037135","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Medded L, Mailhe M et al (2020) Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial. medRxiv. https:\/\/doi.org\/10.1101\/2020.03.16.20037135","journal-title":"medRxiv"},{"key":"2383_CR43","volume-title":"Review of side effects and toxicity of chloroquine","author":"H Weniger","year":"1979","unstructured":"Weniger H (1979) Review of side effects and toxicity of chloroquine. World Health Organization, Geneva"},{"issue":"1a","key":"2383_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","volume":"75","author":"EW McChesney","year":"1983","unstructured":"McChesney EW (1983) Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med 75(1a):11\u201318. https:\/\/doi.org\/10.1016\/0002-9343(83)91265-2(Epub 1983\/07\/18)","journal-title":"Am J Med"},{"key":"2383_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05985-9","author":"H Zhang","year":"2020","unstructured":"Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. https:\/\/doi.org\/10.1007\/s00134-020-05985-9","journal-title":"Intensive Care Med"},{"issue":"1","key":"2383_CR46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H et al (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6(1):16. https:\/\/doi.org\/10.1038\/s41421-020-0156-0","journal-title":"Cell Discov"},{"issue":"8","key":"2383_CR47","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B et al (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11(8):875\u2013879. https:\/\/doi.org\/10.1038\/nm1267(Epub 2005\/07\/12)","journal-title":"Nat Med"},{"issue":"9","key":"2383_CR48","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1128\/MCB.23.9.3247-3252.2003","volume":"23","author":"I Rubio-Aliaga","year":"2003","unstructured":"Rubio-Aliaga I, Frey I, Boll M, Groneberg DA, Eichinger HM, Balling R et al (2003) Targeted disruption of the peptide transporter Pept2 gene in mice defines its physiological role in the kidney. Mol Cell Biol 23(9):3247\u20133252","journal-title":"Mol Cell Biol"},{"key":"2383_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fcimb.2017.00056","volume":"7","author":"N Ding","year":"2017","unstructured":"Ding N, Zhao K, Lan Y, Li Z, Lv X, Su J et al (2017) Induction of atypical autophagy by porcine hemagglutinating encephalomyelitis virus contributes to viral replication. Front Cell Infect Microbiol 7:56. https:\/\/doi.org\/10.3389\/fcimb.2017.00056(Epub 2017\/03\/16)","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"2383_CR50","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","volume":"1824","author":"V Turk","year":"2012","unstructured":"Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B et al (2012) Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochem Biophys Acta 1824(1):68\u201388. https:\/\/doi.org\/10.1016\/j.bbapap.2011.10.002(Epub 2011\/10\/26)","journal-title":"Biochem Biophys Acta"},{"key":"2383_CR51","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.2174\/092986706777935122","volume":"13","author":"R Frlan","year":"2006","unstructured":"Frlan R, Gobec S (2006) Inhibitors of cathepsin B. Curr Med Chem 13:2309\u20132327. https:\/\/doi.org\/10.2174\/092986706777935122","journal-title":"Curr Med Chem"},{"issue":"3","key":"2383_CR52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, Dorner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16(3):155\u2013166. https:\/\/doi.org\/10.1038\/s41584-020-0372-x(Epub 2020\/02\/09)","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"2383_CR53","doi-asserted-by":"publisher","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"ML Agostini","year":"2018","unstructured":"Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X et al (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9(2):e00221\u2013e318. https:\/\/doi.org\/10.1128\/mBio.00221-18","journal-title":"mBio"},{"issue":"10","key":"2383_CR54","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","volume":"382","author":"ML Holshue","year":"2020","unstructured":"Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382(10):929\u2013936. https:\/\/doi.org\/10.1056\/NEJMoa2001191(PubMed PMID: 32004427)","journal-title":"N Engl J Med"},{"key":"2383_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","volume":"1282","author":"AR Fehr","year":"2015","unstructured":"Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol (Clifton, NJ) 1282:1\u201323. https:\/\/doi.org\/10.1007\/978-1-4939-2438-7_1(Epub 2015\/02\/28)","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"issue":"24","key":"2383_CR56","doi-asserted-by":"publisher","first-page":"13600","DOI":"10.1128\/jvi.78.24.13600-13612.2004","volume":"78","author":"BH Harcourt","year":"2004","unstructured":"Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, Smith CM et al (2004) Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol 78(24):13600\u201313612. https:\/\/doi.org\/10.1128\/jvi.78.24.13600-13612.2004(Epub 2004\/11\/27)","journal-title":"J Virol"},{"key":"2383_CR57","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","volume":"115","author":"YM B\u00e1ez-Santos","year":"2015","unstructured":"B\u00e1ez-Santos YM, St John SE, Mesecar AD (2015) The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res 115:21\u201338. https:\/\/doi.org\/10.1016\/j.antiviral.2014.12.015(Epub 12\/29)","journal-title":"Antiviral Res"},{"key":"2383_CR58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1288\/f1000research.22457.1","volume":"9","author":"YW Chen","year":"2020","unstructured":"Chen YW, Yiu C-PB, Wong K-Y (2020) Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res 9:129. https:\/\/doi.org\/10.1288\/f1000research.22457.1","journal-title":"F1000Res"},{"issue":"6","key":"2383_CR59","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.3346\/jkms.2020.35.e79","volume":"35","author":"J Lim","year":"2020","unstructured":"Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ et al (2020) Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35(6):e79. https:\/\/doi.org\/10.3346\/jkms.2020.35.e79(Epub 2020\/02\/15)","journal-title":"J Korean Med Sci"},{"key":"2383_CR60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al (2020) A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2001282","journal-title":"N Engl J Med"},{"key":"2383_CR61","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1021\/acs.jpclett.0c00994","volume":"11","author":"T Huynh","year":"2020","unstructured":"Huynh T, Wang H, Luan B (2020) In silico exploration of the molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2\u2019s main protease. J Phys Chem Lett11:4413\u20134420. https:\/\/doi.org\/10.1021\/acs.jpclett.0c00994","journal-title":"J Phys Chem Lett"},{"key":"2383_CR62","first-page":"75","volume-title":"Nutraceuticals in respiratory disorders","author":"K Gulati","year":"2016","unstructured":"Gulati K, Rai N, Chaudhary S, Ray A (2016) Nutraceuticals in respiratory disorders. Academic Press, Cambridge, pp 75\u201386"},{"issue":"5","key":"2383_CR63","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1513\/AnnalsATS.201411-507FR","volume":"12","author":"S Han","year":"2015","unstructured":"Han S, Mallampalli RK (2015) The role of surfactant in lung disease and host defense against pulmonary infections. Ann Am Thorac Soc 12(5):765\u2013774. https:\/\/doi.org\/10.1513\/AnnalsATS.201411-507FR","journal-title":"Ann Am Thorac Soc"},{"issue":"Suppl 5","key":"2383_CR64","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s15006-017-9805-0","volume":"159","author":"M Plomer","year":"2017","unstructured":"Plomer M, de Zeeuw J (2017) More than expectorant: new scientific data on ambroxol in the context of the treatment of bronchopulmonary diseases. MMW Fortschritte der Medizin 159(Suppl 5):22\u201333. https:\/\/doi.org\/10.1007\/s15006-017-9805-0(Epub 2017\/06\/24)","journal-title":"MMW Fortschritte der Medizin"},{"issue":"3","key":"2383_CR65","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5114\/aoms.2011.23403","volume":"7","author":"X Gao","year":"2011","unstructured":"Gao X, Huang Y, Han Y, Bai C-X, Wang G (2011) The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats. Arch Med Sci 7(3):405\u2013413. https:\/\/doi.org\/10.5114\/aoms.2011.23403(Epub 07\/11)","journal-title":"Arch Med Sci"},{"key":"2383_CR66","unstructured":"Boehringer Ingelheim Limited (2016) Summary of bisolvon product characteristics. https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/LicenseSPC_PA0007-025-002_29042016142022.pdf. Accessed 20 Mar 2020"},{"key":"2383_CR67","unstructured":"Therapeutic Goods Administration (TGA) (2012) Bisolvon chesty product information. https:\/\/gp2u.com.au\/static\/pdf\/B\/BISOLVON_CHESTY-PI.pdf. Accessed 21 Mar 2020."},{"key":"2383_CR68","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coviro.2017.03.018","volume":"24","author":"M Laporte","year":"2017","unstructured":"Laporte M, Naesens L (2017) Airway proteases: an emerging drug target for influenza and other respiratory virus infections. Curr Opin Virol 24:16\u201324. https:\/\/doi.org\/10.1016\/j.coviro.2017.03.018(Epub 2017\/04\/18)","journal-title":"Curr Opin Virol"},{"key":"2383_CR69","unstructured":"Waldrop T, Alsup D, McLaughlin EC (2020) Fearing coronavirus, Arizona man dies after taking a form of chloroquine used to treat aquariums. CNN Health. https:\/\/edition.cnn.com\/2020\/03\/23\/health\/arizona-coronavirus-chloroquine-death\/index.html. Accessed 30 Mar 2020."},{"key":"2383_CR70","doi-asserted-by":"publisher","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","volume":"177","author":"F Touret","year":"2020","unstructured":"Touret F, de Lamballerie X (2020) Of chloroquine and COVID-19. Antiviral Res 177:104762. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104762","journal-title":"Antiviral Res"},{"issue":"8","key":"2383_CR71","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1128\/aac.01509-08","volume":"53","author":"E Keyaerts","year":"2009","unstructured":"Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M et al (2009) Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 53(8):3416\u20133421. https:\/\/doi.org\/10.1128\/aac.01509-08","journal-title":"Antimicrob Agents Chemother"},{"key":"2383_CR72","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.antiviral.2017.11.017","volume":"149","author":"YW Tan","year":"2018","unstructured":"Tan YW, Yam WK, Sun J, Chu JJH (2018) An evaluation of chloroquine as a broad-acting antiviral against hand, foot and mouth disease. Antiviral Res 149:143\u2013149. https:\/\/doi.org\/10.1016\/j.antiviral.2017.11.017(Epub 2017\/11\/28)","journal-title":"Antiviral Res"},{"issue":"2","key":"2383_CR73","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/cr.2012.165","volume":"23","author":"Y Yan","year":"2013","unstructured":"Yan Y, Zou Z, Sun Y, Li X, Xu K-F, Wei Y et al (2013) Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 23(2):300\u2013302. https:\/\/doi.org\/10.1038\/cr.2012.165","journal-title":"Cell Res"},{"issue":"9","key":"2383_CR74","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1473-3099(11)70065-2","volume":"11","author":"NI Paton","year":"2011","unstructured":"Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S et al (2011) Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 11(9):677\u2013683. https:\/\/doi.org\/10.1016\/S1473-3099(11)70065-2","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2383_CR75","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/BF01250299","volume":"36","author":"Y Shimizu","year":"1972","unstructured":"Shimizu Y, Yamamoto S, Homma M, Ishida N (1972) Effect of chloroquine on the growth of animal viruses. Archiv f\u00fcr die gesamte Virusforschung 36(1):93\u2013104. https:\/\/doi.org\/10.1007\/BF01250299","journal-title":"Archiv f\u00fcr die gesamte Virusforschung"},{"issue":"1","key":"2383_CR76","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","volume":"323","author":"E Keyaerts","year":"2004","unstructured":"Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M (2004) In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 323(1):264\u2013268. https:\/\/doi.org\/10.1016\/j.bbrc.2004.08.085(Epub 2004\/09\/08)","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2383_CR77","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1099\/0022-1317-4-2-203","volume":"4","author":"AD Inglot","year":"1969","unstructured":"Inglot AD (1969) Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J Gen Virol 4(2):203\u2013214. https:\/\/doi.org\/10.1099\/0022-1317-4-2-203","journal-title":"J Gen Virol"},{"key":"2383_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237","author":"X Yao","year":"2020","unstructured":"Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa237","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2383_CR79","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/00004714-198202000-00005","volume":"2","author":"MI Good","year":"1982","unstructured":"Good MI, Shader RI (1982) Lethality and behavioral side effects of chloroquine. J Clin Psychopharmacol 2(1):40\u201347. https:\/\/doi.org\/10.1097\/00004714-198202000-00005(Epub 1982\/02\/01)","journal-title":"J Clin Psychopharmacol"},{"issue":"51","key":"2383_CR80","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1016\/j.vaccine.2012.10.001","volume":"30","author":"E Bottcher-Friebertshauser","year":"2012","unstructured":"Bottcher-Friebertshauser E, Lu Y, Meyer D, Sielaff F, Steinmetzer T, Klenk HD et al (2012) Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections. Vaccine 30(51):7374\u20137380. https:\/\/doi.org\/10.1016\/j.vaccine.2012.10.001(Epub 2012\/10\/18)","journal-title":"Vaccine"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-020-02383-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-020-02383-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-020-02383-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T23:42:50Z","timestamp":1621986170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-020-02383-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2383"],"URL":"https:\/\/doi.org\/10.1007\/s11739-020-02383-3","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"19 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that no competing interests exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"No ethics approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any study with humans performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No informed consent is required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}